FLT3 Inhibitors as Sensitizing Agents for Cancer Chemotherapy

Baer, Maria R.

doi:10.1016/b978-0-12-816435-8.00006-7

Search citation statements

Order By: Relevance

Paper Sections

Select...

Flt3 Gene Mutations1

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(2 citation statements)

References 109 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FLT3-ITD mutations occur in 25-35% of all adult AML. However, in pediatric AML, only 5-15% harbor a FLT mutation 31,25,29 and these mutations have been shown to be strong, independent predictors of poor clinical outcome. 31,32 ITD mutations are associated with leukocytosis and increased blast counts, 29 and the presence of a FLT3-ITD mutation is a poor prognostic marker for overall survival (OS), relapse free survival (RFS) and event-free survival (EFS).…”

Section: Flt3 Gene Mutationsmentioning

confidence: 99%

See 1 more Smart Citation

FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms

et al. 2022

View full text Add to dashboard Cite

show abstract

Section: Flt3 Gene Mutationsmentioning

confidence: 99%

“…5,10 Both overexpression of and mutations within the FLT3 gene have been associated with poor prognosis in hematological malignancies. [24][25][26]…”

Section: Introductionmentioning

confidence: 99%

FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms

et al. 2022

View full text Add to dashboard Cite

show abstract

RP-HPLC Method for Determination of Gilteritinib in Tablet Dosage Form

Kharat¹,

Thakur²,

Munipalli³

et al. 2022

IJPSRR

View full text Add to dashboard Cite

The development of pharmaceutical products brought a revolution in human health, but controlling the concentration of drugs in these products is essential to patient’s safety. In this study, a simple, sensitive and specific HPLC method is developed and validated to quantitatively estimate Gilteritinib in pharmaceuticals dosage form. Chromatographic separation was performed on an Hemochrom Intsil C18 Column (250 x 4.6 mm; 5µm) via isocratic elution with mobile phase consisting of 25mm Sodium Perchlorate (pH = 2.0 adjusted with Orthophosphoric acid): acetonitrile (65:35) with a flow rate of 1mL/min. The detection was achieved with UV/Vis detector with a detection wavelength of 310 nm. The method was validated in terms of linearity, sensitivity, precision, accuracy and limit of quantification tests. Gilteritinib can be successfully separated with good linearity (the regression equation is y=41928x + 108090, R2 = 0.9998 and perfect recovery with the results of accuracy were in the range 98-102%.

show abstract

FLT3 Inhibitors as Sensitizing Agents for Cancer Chemotherapy

Cited by 2 publications

References 109 publications

FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms

FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms

RP-HPLC Method for Determination of Gilteritinib in Tablet Dosage Form

Contact Info

Product

Resources

About